Ghost Tree Capital’s Neos Therapeutics, Inc NEOS Stock Holding History

Ghost Tree Capital’s Portfolio NEOS Stock Details NEOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-482,600	Closed	-$2.34M	–	63
2018 Q3	$2.34M	Sell	482,600 -117,400	-20%	-$666K	0.5%	43
2018 Q2	$3.75M	Hold	600,000	–	–	1.1%	32
2018 Q1	$4.98M	Buy	600,000 +300,000	+100%	+$2.86M	1.01%	33
2017 Q4	$3.06M	Sell	300,000 -100,000	-25%	-$960K	0.72%	40
2017 Q3	$3.66M	Sell	400,000 -100,000	-20%	-$760K	0.78%	46
2017 Q2	$3.65M	Buy	+500,000	New	+$3.77M	0.76%	51

Other funds holding NEOS

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ghost Tree Capital's NEOS Position: Q4 2018 in Review

Ghost Tree Capital sold out of Neos Therapeutics, Inc (NEOS) in Q4 2018, closing a stake of 482,600 shares — an estimated $2.34M sold.

Ghost Tree Capital first reported a position in NEOS in Q2 2017 and held it in 6 quarters. The position peaked at $4.98M in Q1 2018. 63 funds tracked by Wall St. Rank hold NEOS as of Q4 2018.

Ghost Tree Capital reported no remaining Neos Therapeutics, Inc position as of Q4 2018 after selling out during the quarter.
Ghost Tree Capital sold 482,600 Neos Therapeutics, Inc shares in Q4 2018, an estimated $2.34M.
Ghost Tree Capital first reported a position in Neos Therapeutics, Inc in Q2 2017 and held it in 6 quarters.
Ghost Tree Capital's Neos Therapeutics, Inc position peaked at $4.98M in Q1 2018.
63 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q4 2018.

Based on Ghost Tree Capital's 13F filing for Q4 2018, filed 14 Feb 2019.